Exactus, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 18, 2020 at 09:00 pm
Share
Exactus, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced total revenue was USD 678,050 compared to USD 60,153 a year ago. Operating loss was USD 2.893 million compared to USD 2.020 million a year ago. Net loss was USD 1.886 million compared to USD 1.852 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.05 a year ago. For the nine months, total revenue was USD 2.045 million compared to USD 215,816 a year ago. Operating loss was USD 7.063 million compared to USD 5.721 million a year ago. Net loss was USD 6.081 million compared to USD 4.181 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.16 a year ago.
Panacea Life Sciences Holdings, Inc. is a holding company organized as a plant-based natural health ingredient and product company. It specializes in the development, manufacturing, research, and distribution of products with natural health and wellness market segment for both humans and animals. The Companyâs subsidiary, Panacea Life Sciences, Inc. (PLS) is engaged in the production, distribution, research, and manufacturing of nutraceuticals, cannabinoids, mushrooms, kratom, and other natural, plant-based ingredients and products. The Company also offers natural remedies within its branded product lines for every aspect of life, including PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure, and PANA Life. It also operates 51,000 square foot current good manufacturing practice (cGMP) facility located in Golden, Colorado. The Company, through Panacea Life Sciences Holdings, Inc., manages six retail locations and a distribution center situated in the Tampa, Florida area.
PANACEA LIFE SCIENCES HOLDINGS, INC. 